AXGN (Axogen) LT-Debt-to-Total-Asset : 0.33 (As of Dec. 2024)

View and export this data going back to 1986. Start your Free Trial

What is Axogen LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Axogen's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.33.

Axogen's long-term debt to total assets ratio declined from Dec. 2023 (0.34) to Dec. 2024 (0.33). It may suggest that Axogen is progressively becoming less dependent on debt to grow their business.

Axogen LT-Debt-to-Total-Asset Historical Data

The historical data trend for Axogen's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen LT-Debt-to-Total-Asset Chart

Axogen Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.26

0.32

0.34

0.33

Axogen Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.34	0.36	0.36	0.35	0.33

Axogen LT-Debt-to-Total-Asset Calculation

Axogen's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	66.717	/	203.728
	=	0.33

Axogen's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	66.717	/	203.728
	=	0.33

Axogen (NAS:AXGN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Axogen LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Axogen's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Axogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

0HKD:UK LT3:Germany LT3:Germany

Address

13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615

Website

https://www.axogeninc.com

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Executives

Erick Wayne Devinney	officer: VP, Clinical&Translational Sc	13631 PROGRESS BLVD SUITE 400, ALACHUA FL 32615
Amy Mcbride Wendell	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Angelo Scopelianos	officer: Chief R&D Officer	C/O AXOGEN, INC., 13631 PROGRESS BOULEVARD - SUITE 400, ALACHUA FL 32615
Karen L. Zaderej	director, officer: CEO	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Michael Patrick Donovan	officer: VP Operations	C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Peter J Mariani	officer: Chief Financial Officer	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Burke William P. Mr.	director	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Marc A Began	officer: EVP & General Counsel	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall	director	13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Maria D. Martinez	officer: Chief Human Resources Officer	C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Mark Stephen Gold	director	13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Paul Thomas	director	ONE MILLENNIUM WAY, BRANCHBURG NJ 08876